CytRx’s Arimoclomol To Be Administered In A Phase 2/Phase 3 Adaptive Clinical Trial In A Subset Of Patients With Familial ALS

CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical company engaged in the development and commercialization of human therapeutics, announced that a Phase 2/3 adaptive clinical trial has commenced to study its molecular chaperone regulator drug candidate arimoclomol in a subset of patients with the inherited or familial form of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease).
This entry was posted in News from Other Sources. Bookmark the permalink. Both comments and trackbacks are currently closed.